Jain Nikunj 4
4 · SANGAMO THERAPEUTICS, INC · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Sangamo (SGMO) Principal Accounting Officer Jain Nikunj Receives Award
What Happened
- Jain Nikunj, Principal Accounting Officer at Sangamo Therapeutics (SGMO), was granted a derivative award on 2026-04-01 for 225,000 shares. The Form 4 reports an acquisition at $0.00 (derivative grant), indicating a stock-based award (option/award), not a cash purchase or sale.
Key Details
- Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (appears timely — filed within two business days).
- Transaction type/code: A — Grant/Award (derivative).
- Quantity and price: 225,000 shares at $0.00; total cash outlay reported = $0.
- Shares owned after transaction: Not specified in the provided filing.
- Footnote: The award is subject to vesting — 1/4 vests on the first anniversary of the grant; the remainder vests in 24 equal monthly installments thereafter, subject to continuous service and the 2018 EIP; acceleration provisions may apply.
- Tax withholding or sale-to-cover: None indicated in the filing.
Context
- This was a grant of a derivative compensation award (per footnote, an option-like grant) that vests over time — not an exercise or a sale. Such grants are common as retention/compensation for executives and do not represent an immediate cash investment or liquidation by the insider.
Insider Transaction Report
Form 4
Jain Nikunj
Principal Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-04-01+225,000→ 225,000 totalExercise: $0.26Exp: 2036-03-31→ Common Stock (225,000 underlying)
Footnotes (1)
- [F1]One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Signature
/s/ Scott Willoughby, Attorney-in-Fact|2026-04-03